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Serum and tissue levels of interleukin-6 (IL-6) have been implicated in the biological phenotype of breast carcinoma. A common G/C
polymorphism at position  174 of the IL-6 promoter can influence the expression level of this gene. We therefore investigated for
associations between this polymorphism and various phenotypic features in a series of 256 breast cancers. Individuals who were
homozygous for the C allele (n¼55) were more likely to have higher-grade tumours (P¼0.039) with ductal histology (P¼0.030)
compared to those harbouring at least one wild-type G allele (n¼201). Homozygosity for the C allele was also associated with
significantly worse overall survival (P¼0.031). We conclude that the  174 C allele of IL-6 is associated with a more aggressive breast
cancer phenotype.
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Interleukin-6 (IL-6) is a pleiotropic growth factor involved in
many physiological and pathological processes including carcino-
genesis (Ishihara and Hirano, 2002). High serum levels of IL-6
have been associated with advanced stage disease and worse
prognosis for several cancer types including ovarian, breast and
colorectal (Berek et al, 1991; Zhang and Adachi, 1999; Belluco et al,
2000; Bachelot et al, 2003). In contrast, however, high levels of IL-6
protein and mRNA expression within the breast carcinoma tissue
have been linked to better prognosis and to a less malignant
phenotype (Basolo et al, 1996; Fontanini et al, 1999; Karczewska
et al, 2000).
A common G/C polymorphism located within the IL-6 promoter
at position  174 has been reported to influence IL-6 expression,
with the G allele being associated with higher expression levels
(Fishman et al, 1998; Terry et al, 2000; Vickers et al, 2002). This
polymorphism has been implicated in a number of chronic disease
conditions including arthritis, coronary heart disease and diabetes
(Fishman et al, 1998; Fernandez-Real et al, 2000; Yudkin et al,
2000). In human cancer, the  174 G/C IL-6 polymorphism does
not appear to be a risk factor for the development of multiple
myeloma or melanoma (Zheng et al, 2000; Martinez-Escribano
et al, 2002). Recent data, however, suggest that the C allele is
associated with an increased risk of colorectal cancer (Landi et al,
2003). Furthermore, in ovarian cancer, the C allele is associated
with an earlier stage of disease and with significantly better
survival (Hefler et al, 2003). In light of the earlier studies linking
serum and tissue IL-6 levels to breast cancer outcomes, the aim of
the present study was to investigate for possible associations
between the  174 G/C IL-6 polymorphism and phenotypic
characteristics of breast cancer.
MATERIALS AND METHODS
Breast cancers
Consecutive cases of breast cancer treated surgically between 1992
and 1993 at the Sir Charles Gairdner or Royal Perth Hospitals in
Perth, Australia, were selected for study. Genomic DNA was
extracted from surgical specimens using standard techniques. The
median age of patients at surgery was 59 years (range 18–93 years)
and the median follow-up time was 57 months (range 2–96
months). Clinical and pathological features of this tumour series
have been described earlier (Soong et al, 1997). Approximately
92% of node-positive and 23% of node-negative patients received
some form of systemic adjuvant therapy. The majority of patients
(495%) were of European Caucasian descent. Successful genotyp-
ing of the  174 G/C IL-6 polymorphism was achieved for 256
cases. Of these, information on nodal status was unavailable for 61
cases, histological grade for 54 cases, histological type for 23 cases,
tumour size for 27 cases, oestrogen and progesterone receptor
status for five cases, ploidy for 98 cases, vascular invasion for 45
cases and erbB2 status for 25 cases. An institutional ethics
committee approved the study.
Genotyping for the  174 G/C IL-6 polymorphism
Genotyping for the  174 G/C IL-6 polymorphism was carried out
using a PCR-based fluorescence (F)-SSCP protocol, essentially as
described earlier by our laboratory for other single-nucleotide
polymorphisms (Powell et al, 2002; Grieu et al, 2004). HEX-
labelled fluorescent primers (Geneworks, Australia) were designed
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in size. The forward primer sequence was 50-AGGAA-
GAGTGGTTCTGCTTC-30 and the reverse primer sequence 50-
CTTTGTTGGAGGGTGAGGGTG-30. PCR was carried out in a
volume of 15ml comprising a mix of 1  reaction buffer, 0.2mM
dioxynucleotide triphosphates, 2.5mM MgCl2, 0.4mM of each
primer and 0.3U Taq polymerase (Qiagen, Australia). Samples
were heated to 941C before addition of DNA template 200 (200ng).
PCR comprised 10min of denaturation at 941C followed by 32
cycles of 45s at 941C, 45s at the 641C annealing temperature and
45s at 721C. Final extension was at 721C for 5min.
For F-SSCP, 2ml of PCR product was mixed with 4mlo f
deionised formamide-loading buffer and denatured at 941C for
3min. A volume of 1ml of this mix was then loaded onto a
nondenaturing 10% polyacrylamide gel and run on the Gel-Scan
2000 DNA fragment analyzer, according to the manufacturer’s
instructions (Corbett Research, Australia). The sample was pulse
loaded for 20s at 1200V, the wells rinsed and the gel run for
90min at 1200V in 0.8  TBE buffer at a constant temperature of
221C. Sequencing of four DNA samples displaying homozygous
banding patterns on F-SSCP gels was carried out in order to
identify the three possible  174G/C IL-6 genotypes.
Statistical analysis
The w
2 test (Pearson statistic) was used to determine associations
between the  174 G/C IL-6 polymorphism and various clinical and
pathological features of the breast tumours. Kaplan–Meier
analysis was used to assess the cumulative survival probabilities
and differences were evaluated using the log-rank test. Cox
regression was used in univariate survival analysis of various
established prognostic factors and for the  174G/C IL-6 genotype.
All P-values are derived from two-tailed statistical tests. Analyses
were carried out using the SPSS statistical software package
(Chicago, IL, USA).
RESULTS
Three distinct banding patterns could be seen for the  174 G/C IL-
6 polymorphism using the F-SSCP genotyping method (Figure 1).
DNA sequencing identified these as CC homozygotes (pattern 1),
GG homozygotes (pattern 3) and the GC heterozygote (pattern 2).
Frequencies for the C and G alleles were 0.43 and 0.57, respectively,
and were in Hardy–Weinberg equilibrium. The C allele frequency
has previously been reported as 0.41 in a large (n¼1109)
community-based Australian study (Chapman et al, 2003), 0.43
in a UK study of 588 individuals (Vickers et al, 2002), 0.40 in
another UK study of 383 healthy individuals (Fishman et al, 1998)
and 0.43 in a study of 121 ovarian cancer patients from Austria
(Hefler et al, 2003).
Tumours showing nonductal histology or well-differentiated
morphology were significantly under-represented in patients who
were homozygous for the C allele (Table 1). Only one out of 25
(4%) tumours with nonductal histology were found in CC
homozygous patients compared to 47 out of 208 (23%) tumours
with ductal histology (P¼0.03). CC homozygous patients also
showed trends for association with larger tumour size, low
oestrogen receptor content, aneuploidy and amplified ErbB2
status, all of which are known features of poor prognosis. No
associations were seen, however, with two other features of poor
prognosis: positive nodal status and the presence of mutant p53.
Kaplan–Meier survival analysis revealed the IL-6  174 CC
genotype was associated with significantly worse overall survival
compared to the GG or GC genotypes (P¼0.031, Figure 2). The
increased relative risk of death associated with homozygosity for
the C allele was shown in univariate survival analysis to be 1.99
(95% confidence interval: 1.05–3.77; Table 2). The established
features of nodal involvement, poor histological grade, large
tumour size and ErbB2 amplification were all found to be
associated with poor outcome in this tumour series (Table 2).
Interestingly, the CC genotype was over-represented in patients
whose tumours showed the three latter characteristics (Table 1).
The CC genotype was not an independent factor for poor survival,
however, in a multivariate model that included nodal status,
histological grade, tumour size and ErbB2 amplification.
DISCUSSION
Epithelial cells of the normal mammary gland constitutively
produce several cytokines including IL-6 (Basolo et al, 1993).
These have been proposed to play a role in the growth and
differentiation of mammary epithelial tissue. The levels of IL-6
mRNA and protein are strongly reduced in invasive ductal
carcinomas, suggesting an inverse relationship between tumour
aggressiveness and the expression of this cytokine (Basolo et al,
1996; Fontanini et al, 1999; Karczewska et al, 2000). Since the
common  174 G/C polymorphism has been linked to reduced
production of IL-6 (Fishman et al, 1998), we hypothesised that this
genetic variant may be associated with a more aggressive breast
cancer phenotype.
We observed that homozygosity for the  174 C allele was
significantly associated with poor histological grade and with
ductal histology, and showed trends for association with larger
tumour size and low oestrogen receptor content (Table 1). In
keeping with this, CC homozygous patients also showed worse
overall survival compared to the GC/GG patient group (Figure 2),
although this was not independent of other established prognostic
factors. Our results indirectly support the earlier observations of
Basolo and co-workers, who showed that a low tumour level of IL-6
correlated with a more aggressive phenotype (Basolo et al, 1996;
Fontanini et al, 1999). The C allele of the  174 G/C polymorphism
has been shown to have lower IL-6 transcription rates and to be
associated with lower expression levels compared to the G allele
(Fishman et al, 1998; Terry et al, 2000; Vickers et al, 2002). This
might explain our observation of an association between the CC
genotype and a more aggressive breast cancer phenotype.
Confirmation of this will require direct comparison between the
 174 G/C genotype and tumour IL-6 expression levels.
At least two other studies have reported an association between
low tissue expression of IL-6 and aggressive tumour behaviour
(Gandour-Edwards et al, 1995; Basolo et al, 1998). Apart from the
current study, however, there has been only one report of an
association between the IL-6  174 G/C polymorphism and tumour
phenotype (Hefler et al, 2003). In contrast to the present results on
breast cancer, these workers found that the C allele was associated
with low stage and good prognosis in ovarian cancer patients. A
possible explanation may be that IL-6 has different roles in
carcinogenesis according to the tumour type.
1 2 3    23212
Figure 1 F-SSCP genotyping for the  174 G/C IL-6 polymorphism in
breast cancer patients. The three different genotypes are indicated by the
banding patterns observed in the gels: (1) CC homozygote; (2) CG
heterozygote; (3) GG homozygote. Not all bands seen by F-SSCP are
shown.
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increased tumour burden and more advanced disease in several
cancer types including colorectal (Belluco et al, 2000), ovarian
(Berek et al, 1991) and breast (Zhang and Adachi, 1999; Bachelot
et al, 2003). In a recent study of colorectal cancer, high serum IL-6
levels were linked to the  174 GG genotype, but only in patients
with advanced disease (Belluco et al, 2003). It is therefore unclear
whether elevated serum levels of IL-6 are a consequence of or a
contributory cause to advanced tumour stage. Further prospective
studies will be required to elucidate the relationships between the
 174 G/C polymorphism, serum IL-6 levels, normal and tumour
tissue IL-6 levels, and the biological phenotype for different
cancers. It will also be interesting to determine whether the  174 C
allele is a risk factor for breast cancer, as was shown recently for
colorectal cancer (Landi et al, 2003).
We have previously shown significant associations in this breast
tumour cohort between polymorphisms in the p53, p21 and
luteinising hormone receptor genes and various phenotypic
features including histological grade, steroid receptor level and
tumour size (Powell et al, 2002, 2003). The present results provide
further evidence that genetic variants associated with known
functional alterations can influence tumour phenotype.
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